RANCHO CORDOVA, Calif., Nov. 4, 2010 /PRNewswire-FirstCall/ —
ThermoGenesis Corp. (Nasdaq:
KOOL), a leading supplier of innovative products and services
that process and store adult stem cells, said today it has signed a
distribution agreement covering China and Hong Kong for its
products used to prepare cell concentrates, including stem cells,
from bone marrow, at the point-of-care and in the laboratory.
The four-year agreement is with Nanshan Memorial Medical
Institute (Nanshan), a progressive regenerative medicine company in
China and Hong Kong that distributes medical products and has
operated multiple, large healthcare facilities, including
hospitals, stem cell banks and research centers. Under the
agreement, Nanshan will have exclusive distribution rights for the
Company’s Res-Q™ 60 BMC (Res-Q) System and the MXP™
MarrowXpress products.
Dr. Lu Daopei is founder and serves as medical director on
behalf of Nanshan. Dr. Lu is a world-renowned hematologist and
expert in the field of hematopoietic stem cell transplants. He
pioneered the first successful syngeneic bone marrow stem cell
transplant in the People’s Republic of China to treat aplastic
anemia and the first allogeneic peripheral blood stem cell
transplant to treat acute leukemia.
“This agreement represents a major milestone in our strategy to
expand the geographic reach of our offerings into a very exciting
market opportunity for the Company,” said J. Melville Engle,
Chairman and Chief Executive Officer of ThermoGenesis. “We believe
Dr. Lu’s reputation as a pioneer in hematological medicine and
leading stem cell expert in China, combined with the strong,
in-country presence of Nanshan, will greatly enhance ThermoGenesis’
ability to achieve timely government approvals and market adoption
of our bone marrow technologies,” he added.
During phase one of the distribution agreeme
‘/>”/>
